A Phase II Study of CTLA Blockade by Ipilimumab Plus Androgen Suppression Therapy in Patients With an Incomplete Response to AST Alone for Metastatic Prostate Cancer

Trial Profile

A Phase II Study of CTLA Blockade by Ipilimumab Plus Androgen Suppression Therapy in Patients With an Incomplete Response to AST Alone for Metastatic Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Antiandrogens
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2018 Planned End Date changed from 18 Nov 2018 to 28 Sep 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 23 Mar 2017 Planned End Date changed from 1 Apr 2018 to 18 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top